CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation‐Mediated c‐Myc Deubiquitylation to Facilitate Mutant TP53 Transcription
Source abstract
Abstract
Abstract Triple‐negative breast cancer (TNBC) is the most malignant subtype of breast cancer. TP53, which has a mutation rate of ≈70%–80% in TNBC patients, plays oncogenic roles when mutated. However, whether circRNAs can exert their effects on TNBC through regulating mutant TP53 has not been well evaluated. In this study, circCFL1, which is highly expressed in TNBC cells and tissues and has prognostic potential is identified. Functionally, circCFL1 promoted the proliferation, metastasis and stemness of TNBC cells. Mechanistically, circCFL1 acted as a scaffold to enhance the interaction between HDAC1 and c‐Myc, further promoting the stability of c‐Myc via deacetylation‐mediated inhibition of K48‐linked ubiquitylation. Stably expressed c‐Myc further enhanced the expression of mutp53 in TNBC cells with TP53 mutations by directly binding to the promoter of TP53, which promoted the stemness of TNBC cells via activation of the p‐AKT/WIP/YAP/TAZ pathway. Moreover, circCFL1 can facilitate the immune escape of TNBC cells by promoting the expression of PD‐L1 and suppressing the antitumor immunity of CD8+ T cells. In conclusion, the results revealed that circCFL1 plays an oncogenic role by promoting the HDAC1/c‐Myc/mutp53 axis, which can serve as a potential diagnostic biomarker and therapeutic target for TNBC patients with TP53 mutations.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Circular RNAs in diseases · Cancer Mechanisms and Therapy · FOXO transcription factor regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Breast Surgery Qilu Hospital of Shandong University Jinan Shandong 250012 P. R. China
School of Basic Medicine Jining Medical College Jining Shandong 272067 P. R. China
Pathology Tissue Bank Qilu Hospital of Shandong University Jinan Shandong 250012 P. R. China
Research Institute of Breast Cancer Shandong University Jinan Shandong 250012 P. R. China
Funding
National Key Research and Development Program of China · China Postdoctoral Science Foundation · Natural Science Foundation of Shandong Province
References (76)
Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.3390/pharmaceutics1310169410.3390/pharmaceutics13101694 ↗
3. 10.1158/2159-8290.CD-20-028810.1158/2159-8290.CD-20-0288 ↗
4. 10.1002/ijc.3448310.1002/ijc.34483 ↗
5. 10.1016/j.trecan.2017.09.00110.1016/j.trecan.2017.09.001 ↗
6. Wahba H. A. · Cancer Biol. Med. · 2015 · 12 · 106
7. 10.1016/j.jprot.2017.08.01010.1016/j.jprot.2017.08.010 ↗
8. 10.3390/biom1109131910.3390/biom11091319 ↗
9. 10.1038/nature1247710.1038/nature12477 ↗
10. 10.1038/nature0344510.1038/nature03445 ↗
11. 10.1002/path.613410.1002/path.6134 ↗
12. 10.1038/s41418-021-00762-710.1038/s41418-021-00762-7 ↗
13. 10.3389/fonc.2020.60412410.3389/fonc.2020.604124 ↗
14. 10.3390/ijms2111408710.3390/ijms21114087 ↗
15. 10.3390/ijms1904118410.3390/ijms19041184 ↗
16. 10.1038/nbt.289010.1038/nbt.2890 ↗
17. 10.1038/nature1192810.1038/nature11928 ↗
18. 10.1016/j.ymthe.2021.01.01810.1016/j.ymthe.2021.01.018 ↗
19. 10.1038/s41419-022-05216-710.1038/s41419-022-05216-7 ↗
20. 10.1186/s13045-022-01345-w10.1186/s13045-022-01345-w ↗
21. 10.1038/onc.2016.51810.1038/onc.2016.518 ↗
22. 10.1038/s41419-024-06505-z10.1038/s41419-024-06505-z ↗
23. 10.1016/j.cell.2018.11.01310.1016/j.cell.2018.11.013 ↗
24. 10.1093/nar/gkv49310.1093/nar/gkv493 ↗
25. 10.1136/annrheumdis-2021-21996910.1136/annrheumdis-2021-219969 ↗
26. 10.1038/cdd.2014.1510.1038/cdd.2014.15 ↗
27. 10.1073/pnas.95.7.351910.1073/pnas.95.7.3519 ↗
28. Fumiaki O. · Mol. Cell · 2016 · 64
29. 10.1016/j.molcel.2017.11.00610.1016/j.molcel.2017.11.006 ↗
30. 10.3389/fendo.2019.0015210.3389/fendo.2019.00152 ↗
31. 10.1038/nrclinonc.2016.6610.1038/nrclinonc.2016.66 ↗
32. 10.1016/j.ccell.2019.02.00110.1016/j.ccell.2019.02.001 ↗
33. 10.1073/pnas.230880712010.1073/pnas.2308807120 ↗
34. Liu J. · J. Clin. Invest. · 2023 · 133
35. 10.3724/abbs.202302110.3724/abbs.2023021 ↗
36. Zhao Y. · J. Exp. Clin. Cancer Res. · 2019 · 38
37. Takahashi R. · Sci. Rep. · 2013 · 3
38. 10.1038/s41388-017-0060-810.1038/s41388-017-0060-8 ↗
39. 10.1038/onc.2016.51810.1038/onc.2016.518 ↗
40. 10.1002/ijc.3044810.1002/ijc.30448 ↗
41. 10.1038/s41568-021-00332-610.1038/s41568-021-00332-6 ↗
42. 10.1038/s41467-021-22971-x10.1038/s41467-021-22971-x ↗
43. 10.1007/s10555-010-9216-510.1007/s10555-010-9216-5 ↗
44. 10.1002/advs.20210265810.1002/advs.202102658 ↗
45. 10.1371/journal.pone.004568410.1371/journal.pone.0045684 ↗
46. 10.1101/cshperspect.a01952110.1101/cshperspect.a019521 ↗
47. 10.1093/cvr/cvab19810.1093/cvr/cvab198 ↗
48. 10.1515/hsz-2017-030610.1515/hsz-2017-0306 ↗
49. 10.1038/cdd.2016.3110.1038/cdd.2016.31 ↗
50. 10.1186/s12943-020-01291-610.1186/s12943-020-01291-6 ↗
51. 10.1016/j.ctrv.2021.10215410.1016/j.ctrv.2021.102154 ↗
52. 10.1186/s12964-023-01043-110.1186/s12964-023-01043-1 ↗
53. 10.1016/j.canlet.2021.11.00610.1016/j.canlet.2021.11.006 ↗
54. 10.3748/wjg.14.596210.3748/wjg.14.5962 ↗
55. 10.1038/s12276-023-01014-z10.1038/s12276-023-01014-z ↗
56. 10.1016/j.redox.2022.10249610.1016/j.redox.2022.102496 ↗
57. 10.1073/pnas.181064711510.1073/pnas.1810647115 ↗
58. 10.1111/j.1582-4934.2005.tb00340.x10.1111/j.1582-4934.2005.tb00340.x ↗
59. 10.1186/s12964-018-0231-410.1186/s12964-018-0231-4 ↗
60. 10.1038/s41421-021-00326-610.1038/s41421-021-00326-6 ↗
61. 10.1016/j.molcel.2020.06.02010.1016/j.molcel.2020.06.020 ↗
62. 10.1038/onc.2016.34410.1038/onc.2016.344 ↗
63. 10.1128/MCB.14.12.780510.1128/MCB.14.12.7805 ↗
64. 10.1016/j.molcel.2017.11.00610.1016/j.molcel.2017.11.006 ↗
65. 10.1016/j.febslet.2014.01.04010.1016/j.febslet.2014.01.040 ↗
66. 10.1002/jcb.2112210.1002/jcb.21122 ↗
67. 10.1186/s13045-019-0779-510.1186/s13045-019-0779-5 ↗
68. 10.1056/NEJMoa150182410.1056/NEJMoa1501824 ↗
69. Stanek L. · Bratisl Lek Listy · 2022 · 123 · 83
70. 10.1038/s43018-022-00339-410.1038/s43018-022-00339-4 ↗
71. 10.1093/jnci/djv30310.1093/jnci/djv303 ↗
72. 10.7150/ijbs.6720010.7150/ijbs.67200 ↗
73. 10.1038/nm86310.1038/nm863 ↗
74. Alexander T. · J. Exp. Clin. Cancer Res. · 2019 · 38
75. 10.1038/s41467-022-34000-610.1038/s41467-022-34000-6 ↗
76. 10.1158/0008-5472.CAN-21-236210.1158/0008-5472.CAN-21-2362 ↗